Previous Article | Next Article 
Infection and Immunity, December 2001, p. 7365-7373, Vol. 69, No. 12
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.12.7365-7373.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Virulence of Leishmania infantum Is
Expressed as a Clonal and Dominant Phenotype in Experimental
Infections
Yves Jean-François
Garin,1,*
Annie
Sulahian,1
Francine
Pratlong,2
Pascale
Meneceur,1
Jean-Pierre
Gangneux,1
Eric
Prina,3
Jean-Pierre
Dedet,2 and
Francis
Derouin1
Laboratoire de Parasitologie-Mycologie,
Hôpital Saint-Louis, U.F.R. Lariboisière, Université
Paris VII,1 and Unité
d'Immunophysiologie et Parasitisme Intracellulaire, Institut
Pasteur,3 Paris, and Laboratoire de
Parasitologie et Centre National de Référence des
Leishmanies, C.H.U. de Montpellier,
Montpellier,2 France
Received 10 May 2001/Returned for modification 16 July
2001/Accepted 15 September 2001
 |
ABSTRACT |
Human Leishmania infantum infection results in a
spectrum of clinical expressions ranging from cutaneous to either
asymptomatic or fatal visceral disease. In this context,
characterization of parasite virulence appears to be relevant as a
biological marker of intrinsic parasitic factors that can affect the
pathology of leishmaniasis. Since parasite populations in naturally
infected hosts are likely to be composed of multiclonal associations,
we first explored the biodiversity of parasite virulence at the
intrastrain level in vitro and in vivo by using 11 clones isolated from
three strains previously known to express different virulence
phenotypes in mice. Subsequently, we studied the course of infection in
mice inoculated simultaneously or successively with strains or clones showing various virulence phenotypes. Analysis of in vitro growth characteristics showed no differences among clones from the different parental strains. By contrast, in vivo experiments evidenced a marked
intrastrain heterogeneity of virulence to mice. One out of five clones
obtained from a virulent strain showed a typical virulence phenotype,
while the remaining four clones had low-virulence profiles, as did the
six clones isolated from two low-virulence strains. In mixed
multiclonal infections, the virulence phenotype was expressed as a
dominant character over the associated low-virulence clones. After a
challenge with either a homologous or a heterologous strain or clone,
virulence phenotypes were conserved and expressed as in naive mice
independently from the preexisting population. These results strongly
suggest that parasite virulence in L. infantum visceral
leishmaniasis is clonal and dominant in nature.
 |
INTRODUCTION |
Parasitic infection with
Leishmania spp. results in a broad spectrum of clinical
diseases in humans. Leishmania infantum is responsible for
most cases of human leishmaniasis in southern Europe and reflects this
diversity with proteiform clinical expressions ranging from cutaneous
leishmaniasis (CL) to either asymptomatic or fatal visceral
leishmaniasis (VL).
The varying clinical expression observed in VL depends on complex
relationships in which not only the genetic potential (3, 4) and/or immunological status of the host (10, 15,
20) but also the proper parasite biodiversity (15, 16, 19,
26) appear as determinant factors. Characterization of
Leishmania polymorphism at the species and subspecies levels
is currently based on isoenzyme and biomolecular analysis. However,
identification of biological markers like parasite tropism or virulence
remains crucial as a complementary tool to account for the considerable biodiversity of the parasite.
In this context, characterization of parasite virulence, i.e., the
ability to develop and multiply in vitro and/or in vivo appears
particularly relevant for analysis of parasitic factors that can affect
the pathology of VL. Using 21 Mediterranean strains of L. infantum isolated from humans, we previously showed that there is
a remarkable intraspecific heterogeneity in experimental virulence
expression of the parasite in BALB/c mice (29). Three major infection profiles were characterized: a visceralization (V)
profile with persistent heavy liver parasite burdens and marked progressive spleen involvement, a regulation (R) profile in which the
infection is finally contained after an initial phase involving both
organs, and an undetermined (U) profile with undetectable, low-level,
or poorly characterized infection. Both the V and R profile types were
maintained in C57BL/6 mice (cure haplotype) (17) and also
in CB-17 congenic immunodeficient scid mice, although heavier parasite loads were observed in scid mice than in
BALB/c mice in the late phase of infection (12). Thus, as
these infection profiles are observed in various genetic and
immunological host contexts, they actually characterize parasite
virulence phenotypes in vivo.
Because the population structure of Leishmania spp. and
other kinetoplastids is mainly clonal (8, 18, 30) and
because strains isolated from naturally infected hosts are likely
composed of multiclonal parasite associations (7, 25),
such virulence profiles have to be investigated at the clonal level
before any conclusion about the genotypic nature of parasite virulence
can be drawn. Thus, this work was undertaken to explore the
polymorphism of L. infantum at the intrastrain level and its
possible impact on the basis of virulence phenotyping. Using a mouse
model of VL, we studied the virulence biodiversity of L. infantum clonal populations issuing from strains with various
levels of virulence. We also experimentally investigated the
interaction between strain and clone populations with diverse levels of
virulence when simultaneously or successively present in the same host.
 |
MATERIALS AND METHODS |
Parasites.
The strains and clones used in this study were
from the International Leishmania Cryobank and
Identification Center in Montpellier, France. Three L. infantum strains were selected for their different infection
profiles, as defined in previous experimental studies (29): (i) strain MHOM/FR/91/LEM 2259 zymodeme MON-1
expressing a virulence (V) profile, in which parasite burdens rise
continuously in the spleen (106
to107 ml
1 at day 100)
while persisting at high levels in the liver (LEM 2259/V); (ii) strain
MHOM/FR/91/LEM 2176 (MON-33), previously known as having a regulation
(R) profile in which liver and spleen involvement is observed at the
early phase of infection and followed by regulation with parasite
burdens decreasing to low or undetectable levels in the liver while
remaining moderate in the spleen (LEM 2176/R); and (iii) strain
MHOM/FR/94/LEM 2859 (MON-1), expressing an uncharacterized (U)
phenotype consisting of low-level or even undetectable infection (LEM
2859/U). Both strains LEM 2259/V and LEM 2176/R were isolated from the
bone marrow of human immunodeficiency virus-infected patients with VL.
Strain LEM 2859/U originated from the skin of an immunocompetent patient.
Clones were derived from these strains by the hanging-drop method using
promastigotes at the mid-log phase of growth (1). Five,
four, and two clones were obtained from strains LEM 2259, LEM 2176, and
LEM 2859, respectively.
In vitro culture.
For in vitro growth characteristic study,
parasites were cultivated at 27°C in Schneider's drosophila medium
(SDM) (GIBCO BRL) and HOSMEM liquid medium (2)
supplemented with hemin 10 µM (Sigma) and 20% heat-inactivated fetal
calf serum (GIBCO). Parasites were inoculated into 25-ml culture flasks
at day 0 at a final concentration of 105
ml
1. Parasite concentrations were evaluated by
means of nucleoside hydrolase activity determination using
p-nitrophenyl-
-D-ribofuranoside substrate. Nucleoside hydrolase activity was measured at day 4 and day
7 in duplicate samples of culture supernatants in 96-well microplates
as previously described (13). Parasite concentrations (per
milliliter) in samples were calculated from a standard curve established with a serial twofold dilution of a promastigote suspension made in duplicate from 2 × 107 to 5 × 103 parasites ml
1. For
animal inoculation, mass cultures were produced in SDM.
Experimental animal infection.
Female 8-week-old BALB/c mice
(IFFA CREDO) housed under standard conditions were used. Groups of mice
were inoculated intravenously (i.v.) with 6-day-old promastigotes of
the different strains or clones. The kinetics of infection was
monitored throughout the experiment by determining the parasite burdens
in the livers and spleens of three to five mice for each group at each
measurement point.
Parasite burdens.
Parasites in organs were quantified by
means of a culture microtitration assay as previously described
(5). Briefly, organs were excised, weighed, and then
homogenized with a tissue grinder (ULTRATURRAX, Stauffen, Germany) in 4 ml of SDM supplemented with 20% heat-inactivated fetal calf serum,
penicillin (100 U/ml), and streptomycin (50 µg/ml) (Bio-Merieux).
Serial fourfold dilutions of organ homogenates, ranging from 1/1 to
1/4 × 106, were made in duplicate under
sterile conditions in 96-well microtitration plates containing 225 µl
of culture medium. Plates were examined for the presence of mobile
promastigotes under an inverted microscope after 10 days of incubation
at 26°C. The final titer was the last dilution containing at least
one parasite. Results were expressed as the logarithmic mean number of
parasites per gram established from three to five mice for each group.
The detection threshold of the method is 5 × 102 parasites g
1.
Experimental design.
Three sets of experiments were carried
out (Fig 1). (i) The first set of
experiments was carried out in order to explore intrastrain virulence
biodiversity. For that study, the virulence phenotypes of strains LEM
2259/V, LEM 2176/R, and LEM 2859/U and 11 clones were characterized.
Groups of 16 mice were infected at day 0 with each strain or clone, and
the kinetics of infection was monitored from day 7 to day 98 as shown
in Fig 1a. (ii) A second set of experiments was designed to determine
the kinetics of infection in mice injected simultaneously with clones
with various virulence phenotypes. Infections were done with mixtures
of clones that expressed different virulence profiles in the first
experiment. Three clones originating from strain LEM 2259/V were
selected, virulent clone 3511/V and less pathogenic clones 3518/R and
3512/R. An equal mixture of two or three clones (2 × 106 promastigotes each) was injected into mice at
day 0, and the evolution of the infection was monitored in their livers
and spleens at day 21, day 40, and day 90 (Fig 1b). (iii) The third set
of experiments was carried out to study the interactions between successive primary and challenge infections with strains or clones expressing various pathogenic phenotypes.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 1.
Experimental design of single or concurrent animal
infections. Panels: a, single infections with strains or clones; b,
single infections with mixed clones; c, successive infections with
strains; d, successive infections with clones.
|
|
Groups of mice (
n = 48) were first infected at day 0 with 10
7 promastigotes of strain LEM 2259/V, LEM
2176/R, or LEM 2859/U.
The animals in each group were then either
challenged at day 70
with 10
7 promastigotes of
the same strain or a heterologous strain or
not reinfected
(
n = 12 each). Naive uninfected mice were also
inoculated at day 70 as a control for the challenge inoculum.
Liver and
spleen parasite burdens were measured at day 9, day
31, and day 70 and
then at day 80, day 98, and day 143 in order
to monitor the kinetics of
infection before and after the challenge
infection (Fig
1c).
Similarly, cross-infections were carried out with three clones of
strain LEM 2259/V. Two groups of animals were infected at
day 0 with
nonvirulent clone 3514/R or 3515/U. Six to eight mice
in both groups
were then either challenged at day 66 with clone
3511/V or not
reinfected. A group of eight mice infected with
clone 3515/U was also
challenged at day 66 with clone 3514/R.
Naive mice were also used at
day 66 as a control for the secondary
infection. Animals were
sacrificed at day 7, day 21, and day 66
and then at day 74, day 95, and
day 152 (Fig
1d).
Serological studies.
Serum antibody levels were monitored in
cross-infections (experiment iii) before the challenge infection and at
the end of the experiment.
Antibody titers were determined with an enzyme-linked immunosorbent
assay method using a crude extract of strain LEM 2259/V
as the coating
reagent (5 µg ml
1 in 0.1 M carbonate buffer,
pH 9.4) as described by Honoré et
al. (
17). Pools of
sera were made for each group of mice at
each control point, i.e., day
70 or day 66 after the primary infection
and then after a challenge
(day 98 or day 152). Pooled sera diluted
1/200 were tested in
duplicate. Anti-
Leishmania antibodies were
detected with
biotin-labeled antibodies against mouse immunoglobulin
G (1/2,000;
Dako), streptavidin/peroxidase (1/2,000; Boehringer),
and then
2,2'-azino-di-[3-ethylbenzthiazoline sulfonate] diammonium
(ABTS)
substrate
(Boehringer).
Results were expressed as arbitrary units (AU). The reaction cutoff was
determined in a preliminary assay as the mean number
of AU + 2 standard
deviations established from five uninfected
mice.
Statistical analysis.
Data were analyzed with GraphPad Prism
3.0 statistical software (GraphPad Software). For better comparison of
data from separate experiments in which there were mild variations in
the dates of examination, we chose to present data extrapolated from
the regression curves calculated by using Pearson's correlation
analysis. Thus, for in vitro studies, parasite concentrations (per
milliliter) at day 4 and day 7 were calculated from the regression
equation of the promastigote growth curve. Similarly, for in vivo
experiments, liver and spleen parasite burdens (per gram) were
extrapolated from the corresponding regression lines of parasite
burdens. Thus, parasite loads were calculated at day 7 and day 100 for
single infections and at day 7 and day 65 or day 70 (before
reinfection) and day 75 or day 80 and then day 150 in challenge
experiments. Comparisons were made by one-way analysis of variance
(ANOVA) with Bonferroni's posttests or by two-way ANOVA. For
two-way-ANOVA comparisons, the area under the curve was chosen as a
global estimate of parasite growth in vitro or virulence in animals
(24).
 |
RESULTS |
Characterization of clones.
The in vitro growth
characteristics of the three strains and their respective clones are
summarized in Table 1. All of the strains
and clones grew readily, with a 1- to nearly 3-log increase in parasite
concentration from day 0 to day 7, except for strains LEM 2259 and LEM
2859 in SDM. Promastigote growth rates in the two media were not
correlated (r2 = 0.296, P = 0.32). Promastigote growth was significantly better in HOS culture medium than in SDM (P = 0.005).
Characterization of virulence in vivo (experiment i) is shown in Table
2 and Fig.
2. No deaths or clinical symptoms were
observed in infected mice. However, based on the number of parasites
recovered from their livers and spleens, a great heterogeneity
in the
strain and clone virulence profiles was evidenced.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 2.
Experiment i. Calculated parasite loads ± the standard errors at day 7 (column 1) and day 100 (column 2). Mice
were inoculated i.v. at day 0 with 107 promastigotes of
L. infantum LEM 2259/V, LEM 2176/R, and LEM 2859/U ( )
or their respective clones ( ).
|
|
Mice inoculated with strains LEM 2259/V, LEM 2176/R, and LEM 2859/U
showed the expected type of infection profile observed
previously. Mice
injected with strain LEM 2259/V developed a V
type of infection with
parasite burdens persisting at high levels
in the liver at day 100 (1.6 × 10
5 g
1) and
increasing from 2 × 10
5 to 1.4 × 10
7 g
1 in the spleen.
Inoculation with strain LEM 2176/R resulted in
a controlled infection
with parasite burdens decreasing from 10
4
g
1 at day 7 to undetectable levels at day 100 in the liver while
remaining at low levels (<10
3
g
1) in the spleen. No parasite was detected in
the livers and spleens
of mice inoculated with strain LEM 2859/U.
Among the five clones obtained from strain LEM 2259/V, clone 3511 showed a typical V phenotype. With this clone, liver parasite
burdens
remained at levels of >1.5 × 10
5
g
1 throughout the experiment. In the spleen, a
3-log increase was
observed from day 7 to day 100, reaching 8.3 × 10
6 g
1. This profile
contrasted strongly with those observed with the
other clones
originating from strain LEM 2259/R. In mice inoculated
with clones
3512, 3514, and 3518, a controlled R type of infection
was observed. In
these mice, parasite burdens decreased to very
low or undetectable
levels in the liver while not exceeding 10
4
g
1 in the spleen. Infection with the last
clone, 3515, resulted
in low involvement of both the liver and spleen
(U). The virulence
profile difference between clone 3511/V and each of
the four other
clones of strain LEM 2259 was highly significant in both
the liver
(ANOVA,
P = 0.0004; Bonferroni's posttest,
P = 0.01 to 0.0001)
and the spleen (ANOVA,
P = 0.004; Bonferroni's posttest,
P <0.05
to 0.01).
A great variability in virulence expression was also noted between
clones of strains LEM 2176/R and LEM 2859/U. However, no
clone from
these two strains expressed a virulence phenotype in
mice. An R profile
of infection was observed in mice inoculated
with three clones from
strain LEM 2176/R (clones 3547, 3576, and
3648) and one from strain LEM
2859/U (clone 3721), whereas a U
profile was obtained with the last two
clones, 3550 (strain LEM
2176/R) and 3646 (strain LEM 2859/U).
Mixed infections with clones.
Evolution of infection in mice
injected with mixtures of clones (experiment ii) is represented in Fig.
3. Inoculation with a mixture of clones
3512/R and 3518/R resulted in a controlled R type of infection. The
parasite burden decreased in the liver from 4.7 × 103 at day 7 to 1.7 × 103 g
1 at day 100 while
remaining at a low level in the spleen (3.3 × 103 g
1 at day 100). This
contrasted strongly with the evolution of infection in mice inoculated
simultaneously with clone 3511/V and clone 3512/R, 3518/R, or both
(P <0.001). Despite a reduction in parasite burdens in the
liver, a straightforward (2- to 2.5-log) increase occurred constantly
in the spleen. At day 100, parasite loads reached 5.5 × 105 to 1.6 × 106
g
1. Thus, the virulence phenotype of clone
3511/V was expressed in the three groups of mice, whatever the R clone
coinjected.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 3.
Experiment ii. Calculated parasite burdens ± the
standard errors at day 7 (column 1) and day 100 (column 2). Mice were
inoculated i.v. simultaneously at day 0 with 106
promastigotes of each of two or three clones of L.
infantum strain LEM 2259/V. The three clones used expressed
either a V (clone 3511) or an R (clones 3512 and 3518) phenotype when
inoculated separately. Combinations of clones 3212 and 3218 (R and R
phenotypes, respectively; ), 3511 and 3512 or 3518 (V and R
phenotypes, respectively; ), and 3511, 3512, and 3518 (V, R, and R
phenotypes, respectively; ) were used.
|
|
Cross-infections.
The kinetics of infection in mice inoculated
with strains with various levels of virulence (experiment iiia) are
shown in Fig. 4. Single inoculations with
strains LEM 2259, LEM 2176, and LEM 2811 resulted in V, R, and U
infection profiles, respectively, as already described. In mice
primarily infected with strain LEM 2259/V (Fig. 4A), the infection
profile was not modified after a challenge at day 70 with the same
strain or heterologous strain LEM 2176/R, except for a weak increase in
the liver burden at day 80. By contrast, profound changes in the
kinetics of infection were observed after reinfection in mice
previously infected with strain LEM 2176/R (Fig. 4B) or LEM 2859/U
(Fig. 4C). Similar modifications occurred in both groups of mice. A
challenge infection with strain LEM 2259/V resulted in massive organ
involvement, with parasite burdens reaching levels of
>106 g
1 in the liver and
>107 g
1 in the spleen at
day 150. By contrast, a new infection at day 70 with strain LEM 2176/R
resulted in only a weak increase in the hepatic and splenic burdens at
day 80, followed by control of the challenge infection (Fig. 4B and C).
Thus, the virulence phenotype of strain LEM 2259/V was constantly
expressed in both primary and challenge infections. All groups of mice
primarily infected and/or challenged with this strain showed very heavy parasite burdens at day 150 in the liver (105 to
106 g
1) and especially in
the spleen (>107 g
1).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 4.
Experiment iii. Kinetics of parasite burdens in the
livers ( ) and spleens ( ) of mice successively inoculated i.v. at
day 0 and then at day 70 with 107 promastigotes of three
strains of L. infantum. The primary inoculation was done
with strain LEM 2259/V (A), LEM 2176/R (B), or LEM 2859/U (C)
expressing a V, R, or U phenotype, respectively. The challenge
inoculation at day 70 was done with either the primary infecting strain
or a heterologous strain.
|
|
Similar results were obtained in cross-infection experiments with three
different clones of strain LEM 2259/V (experiment
iiib) (Fig.
5). In mice infected at day 0 by
low-virulence clone
3514/R or 3515/U, the challenge infection at day 66 with virulent
clone 3511/V resulted in a massive infection, with
parasite burdens
reaching 1.5 × 10
6 to
1.9 × 10
6 g
1 in the
liver and progressively increasing to a level of 2 × 10
7 g
1 in the spleen at
the end of the experiment. By contrast, mice
infected at day 0 with
clone 3515/U showed a controlled R type
of infection after a challenge
with clone 3514/R, as previously
observed in single infections with
this clone. In these mice,
after the challenge infection, parasite
burdens remained quite
low (maximum, 5.7 × 10
4 g
1) until day 150 in
the spleen while decreasing to undetectable
levels after a transient
rise at day 80 (2.7 × 10
4
g
1) in the liver.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 5.
Experiment iii. Evolution of parasite burdens in the
livers ( ) and spleens ( ) of mice successively inoculated i.v. at
day 0 and then at day 66 with 107 promastigotes of three
clones of L. infantum strain LEM 2259/V. The clones used
expressed V (clone 3511), R (clone 3514), and U (clone 3515)
phenotypes.
|
|
Serological studies.
In uninfected mice, the mean titer was
158 ± 8.6 AU, determining a positive cutoff of 175 AU. On this
basis, a significant antibody response was observed in all groups of
infected mice (Table 3).
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Anti-Leishmania immunoglobulin G antibody
response in pooled sera from mice cross-infected with L. infantum strains and clones with various levels of
virulencea
|
|
A strong antibody response was elicited by strain LEM 2259/V at day 70, before the challenge infection (683 AU). This contrasted
with the low
antibody levels observed at the same time after infection
with strain
LEM 2176/R, i.e., 343 AU. At day 70, a significant
antibody response
(267 AU) was also noted in mice inoculated with
strain LEM 2859/U,
although no parasites were detected in this
group of mice. Mice
primarily inoculated with strain LEM 2176/R
or LEM 2859/U showed a net
antibody level increase (

30%) after
a challenge with strain LEM
2259/V (476 and 346 AU at day 98,
respectively), while no change was
observed after a challenge
infection with strain LEM 2176/R. In mice
first infected with
strain LEM 2259/V, the antibody response remained
unchanged until
the end of the experiment whatever the strain used for
the secondary
infection.
Similar results were observed in mice infected with clones. A weak
antibody response was elicited after inoculation with clones
3514/R
(395 AU) and 3515/U (260 AU). By contrast, infection with
V clone
3511/V was accompanied with a strong and persistent serological
response, 580 and 477 AU at day 66 and day 152, respectively.
In mice
preinoculated with clone 3514/R or 3515/U and then reinfected
with
clone 3511/V at day 66, a straightforward antibody level
increase was
observed after the challenge, reaching 470 and 410
AU at day 152, respectively. By contrast, in mice infected with
clone 3515/U and then
challenged with clone 3514/R, antibodies
decreased to an insignificant
level (175 AU) at day
152.
 |
DISCUSSION |
Genetic diversity is a crucial parameter that must be
taken into account in human VL. In particular, polymorphism of parasite virulence and tropism is likely to have a profound impact on disease transmission and/or pathology, as suggested by experimental studies on
L. guyanensis CL in hamsters and Trypanosoma
cruzi trypanosomiasis in mice (11, 22).
Phenotypic characterization is a prerequisite for further
identification of genetic loci and/or mechanisms involved in parasite tropism and virulence. Phenotypic analysis of Leishmania
isolates is currently based largely on isoenzyme polymorphism
(27). Thus, dermotropic and viscerotropic human L. infantum zymodemes have been identified (15).
However, we have previously shown that this method cannot discriminate
between parasites with various levels of virulence since strains of
L. infantum belonging to the same zymodeme exhibit a large
heterogeneity of virulence profiles in mice (29).
In a first attempt to investigate the biodiversity of virulence
expression of L. infantum parasites at the intrastrain
level, we analyzed the in vitro and in vivo growth characteristics of three strains (isolated from humans) that exhibit different virulence patterns in mice, as well as those of 11 clones originating from these
strains. Analysis of parasite growth characteristics in vitro showed no
differences among clones from the different parental strains. By
contrast, a marked intrastrain heterogeneity was evidenced by in vivo
virulence phenotype analysis. One out of five clones obtained from the
V strain generated a typical V profile, with marked and prolonged
involvement of the liver and spleen until the end of the experiment,
while the four remaining clones showed low-virulence infection profiles
(three R and one U). No virulent clone was obtained from the two
strains selected for their nonvirulence or undetermined phenotype.
Clones obtained from these strains gave four R and two U types of
infection. Thus, we can conclude that strains are composed of
multiclonal parasite populations that are heterogeneous on the basis of
experimental virulence in mice.
As a consequence, we examined the course of infection in cases of
concurrent infections with clones in order to investigate the character
of dominance of the V or R phenotype. First, we used several
combinations of two or three clones issuing from the same parental
strain, LEM 2259/V, but displaying various virulence profiles when
injected alone (one V and two R clones). In this experiment, the
presence of the V clone in the inoculum consistently resulted in a V
type of infection whatever the R clone(s) coinjected. This shows that
virulence is expressed as a dominant character in experimental
multiclonal infections without any apparent interaction with the
associated low-virulence clonal populations.
Second, we examined the outcome of infection in cases of sequential
inoculations with strains or clones with different virulence phenotypes. We found that the expression of strain or clone virulence phenotypes was not modified in successive infections of the same host.
The course of infection in previously infected animals was identical to
that observed in naive mice, whatever the combination of virulence
phenotypes used for the primary and secondary inoculations.
To our knowledge, this is the first data concerning the interactions of
parasites varying in virulence in successive experimental VL
infections. Using the same L. infantum strain for primary
and challenge infections, Rousseau et al. (28) found that
a primary infection induced a protective effect that was organ
dependent, protection being achieved in the liver but not in the
spleen. In CL, previous experiments on the protective role of a primary infection against a challenge have led to contradictory results. Li et
al. (21) observed that infection of BALB/c mice with a low-virulence clone of L. major protected mice against a
challenge infection with a highly virulent clone. Our results are more
in agreement with those of Da Fonseca et al. (9), who
showed that a primary infection with a totally avirulent strain of
L. amazonensis did not protect mice against a virulent strain.
Serological studies showed that the type of infection significantly
influenced the humoral response in mice. Indeed, a serological response
was detected in all infected mice, including those inoculated with
low-virulence strains or clones. However, mice inoculated with a
virulent strain or clone showed higher antibody levels than did animals
infected with less virulent parasite populations. Similarly, a
challenge infection with a V strain or clone was followed by a marked
increase in antibody levels while no changes were observed after a
challenge with an R strain or clone. This shows that progression of
infection is accompanied by a humoral response in both primarily
infected or superinfected animals. This correlates with observations
made in human VL, where patent infections are frequently associated
with a strong specific antibody response and T-cell anergy to
Leishmania antigen (14), while a cure is
accompanied by an antibody level decrease and restoration of the
cellular response (6, 23).
Our results clearly show that (i) L. infantum strains
isolated from humans are composed of clonal populations displaying a marked polymorphism of experimental virulence to mice, (ii) populations with various levels of virulence do not interact in vivo in
experimental multiclonal infections and strain and/or clone virulence
phenotypes are conserved in simultaneous or successive infections, and
(iii) the virulence phenotype is expressed as a dominant character in such experimental infections with different parasite populations. This
may have a profound impact on the epidemiology and immunopathology of
L. infantum VL. Characterization of parasite virulence is a crucial step that must be done in parallel with immunological or
biomolecular research studies on VL.
 |
ACKNOWLEDGMENTS |
We thank M. Lambert for cloning of the strains.
The Centre National de Référence des Leishmanioses received
financial support from the Ministry of Health.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratoire de
Parasitologie-Mycologie, 15 rue de l'Ecole de Médecine, 75270 Paris Cédex 06, France. Phone: 33 1 43 29 65 25. Fax: 33 1 43 29 51 92. E-mail: jfgarin{at}bhdc.jussieu.fr.
Editor:
S. H. E. Kaufmann
 |
REFERENCES |
| 1.
|
Bastien, P., and M. Wahba.
1989.
A simplification of the technique for cloning Leishmania.
Ann. Trop. Med. Parasitol.
83:435-437[Medline].
|
| 2.
|
Berens, R. L., and J. J. Marr.
1978.
An easily prepared defined medium for cultivation of Leishmania donovani promastigotes.
J. Parasitol.
64:160[CrossRef][Medline].
|
| 3.
|
Blackwell, J. M.
1996.
Genetic susceptibility to Leishmania infections: studies in mice and man.
Parasitology
112:S67-S74.
|
| 4.
|
Bradley, D.
1977.
Regulation of Leishmania populations within the host. II. Genetic control of acute susceptibility of mice to Leishmania donovani infections.
Clin. Exp. Immunol.
30:130-140[Medline].
|
| 5.
|
Buffet, P.,
A. Sulahian,
Y. J. F. Garin,
N. Nassar, and F. Derouin.
1995.
Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice.
Antimicrob. Agents Chemother.
39:2167-2168[Abstract].
|
| 6.
|
Carvalho, E. M.,
O. Bacellar,
C. Brownell,
T. Regis,
R. L. Coffman, and S. G. Reed.
1994.
Restoration of the IFN- production and lymphocyte proliferation in visceral leishmaniasis.
J. Immunol.
152:5949-5956[Abstract].
|
| 7.
|
Cuba-Cuba, C. A.,
D. Evans,
A. de C. Rosa, and P. D. Mardsen.
1991.
Clonal variation within a mucosal isolate derived from a patient with Leishmania (Viannia) braziliensis infection.
Rev. Inst. Med. Trop. São Paulo
33:343-350[Medline].
|
| 8.
|
Cupolillo, E.,
G. Grimaldi, and H. Momen.
1997.
Genetic diversity among Leishmania (Viannia) parasites.
Ann. Trop. Med. Parasitol.
91:617-626[CrossRef][Medline].
|
| 9.
|
Da Fonseca, A. L. S.,
A. L. Vallochi,
G. de Furtado,
I. de Abrahamsohn, and G. M. Lima.
1997.
Immune response and protection in mice inoculated with Leishmania amazonensis clones expressing different degrees of virulence.
Parasitol. Res.
83:690-697[CrossRef][Medline].
|
| 10.
|
Dedet, J. P.,
F. Pratlong,
G. Lanotte, and C. Ravel.
1999.
Cutaneous leishmaniasis. The parasite.
Clin. Dermatol.
17:261-268[Medline].
|
| 11.
|
De Lana, M.,
A. da Silveira Pinto,
B. Bastrenta,
C. Barnabé,
S. Noël, and M. Tibayrenc.
2000.
Trypanosoma cruzi: infectivity of clonal genotype infections in acute and chronic phase in mice.
Exp. Parasitol.
96:61-66[CrossRef][Medline].
|
| 12.
|
Gangneux, J. P.,
A. Sulahian,
S. Honore,
P. Meneceur,
F. Derouin, and Y. J. F. Garin.
2000.
Evidence for determining parasitic factors in addition to host genetics and the immune status in the outcome of murine Leishmania infantum visceral leishmaniasis.
Parasite Immunol.
22:515-519[CrossRef][Medline].
|
| 13.
|
Garin, Y. J. F.,
A. Sulahian,
P. Meneceur,
J. P. Gangneux,
C. Pannier-Stockman, and F. Derouin.
2001.
Assessment of Leishmania promastigote growth in vitro by means of nucleoside hydrolase activity determination.
Parasitol. Res.
87:145-148[CrossRef][Medline].
|
| 14.
|
Ghalib, H. W.,
M. R. Piuvezam,
Y. A. W. Skeiky,
M. Siddig,
F. A. Hashim,
A. M. El Hassan,
D. M. Russo, and S. G. Reed.
1993.
Interleukin 10 production correlates with pathology in human Leishmania donovani infections.
J. Clin. Investig.
92:324-329.
|
| 15.
|
Gradoni, L., and M. Gramiccia.
1994.
Leishmania infantum tropism: strain genotype or host immune status?
Parasitol. Today
10:264-267[Medline].
|
| 16.
|
Gramiccia, M.,
L. Gradoni, and M. C. Angelici.
1989.
Epidemiology of Mediterranean leishmaniasis by Leishmania infantum: isoenzyme and kDNA analysis for the identification of parasites from man, vectors and reservoirs.
NATO-ASI Ser. Ser. A Life Sci.
1:21-37.
|
| 17.
|
Honoré, S.,
Y. J. F. Garin,
A. Sulahian,
J. P. Gangneux, and F. Derouin.
1998.
Influence of the host and parasite strain in a mouse model of visceral Leishmania infantum infection.
FEMS Immunol. Med. Microbiol.
21:231-239[Medline].
|
| 18.
|
Jiménez, M.,
J. Alvar, and M. Tibayrenc.
1997.
Leishmania infantum is clonal in AIDS patients too: epidemiological implications.
AIDS
11:569-573[CrossRef][Medline].
|
| 19.
|
Jiménez, M.,
M. Ferrer-Dufol,
C. Cañavate,
B. Gutiérrez-Solar,
R. Molina,
F. Laguna,
R. López-Vélez,
E. Cercenado,
E. Daudén,
J. Blázquez,
C. Ladrón de Guevara,
J. Gómez,
J. De la Torre,
C. Barros,
J. Altés,
T. Serra, and J. Alvar.
1995.
Variability of Leishmania (Leishmania) infantum among stocks from immunocompromised, immunocompetent patients and dogs in Spain.
FEMS Microbiol. Lett.
131:197-204[Medline].
|
| 20.
|
Kubar, J.,
P. Marty,
A. Lelievre,
J. F. Quaranta,
P. Staccini,
C. Caroli-Bosc, and Y. Le Fichoux.
1998.
Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts.
AIDS
12:2147-2153[CrossRef][Medline].
|
| 21.
|
Li, J.,
T. J. Nolan, and J. P. Farrell.
1997.
Leishmania major. A clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
Exp. Parasitol.
87:47-57[CrossRef][Medline].
|
| 22.
|
Martinez, J. E.,
L. Valderrama,
V. Gama,
D. A. Leiby, and N. G. Saravia.
2000.
Clonal diversity in the expression and stability of the metastatic capability of Leishmania guyanensis in the golden hamster.
J. Parasitol.
86:792-799[CrossRef][Medline].
|
| 23.
|
Mary, C.,
D. Lamouroux,
S. Dunan, and M. Quilici.
1992.
Western blot analysis of antibodies to Leishmania infantum antigens: potential of the 14-kD and 16-kD antigens for diagnosis and epidemiologic purposes.
Am. J. Trop. Med. Hyg.
47:764-771.
|
| 24.
| Motulsky, H. 10 July 1998. Comparing dose-response
or kinetic curves with GraphPad Prism. HMS Beagle BioMedNet Magazine
34. [Online.] http: //news.bma.com/hmsbeagle.
|
| 25.
|
Pacheco, R. S.,
G. Grimaldi,
J. R., H. Momen, and C. M. Morel.
1990.
Population heterogeneity among clones of New World Leishmania species.
Parasitology
100:393-398.
|
| 26.
|
Pratlong, F.,
J. P. Dedet,
P. Marty,
M. Portus,
M. Deniau,
J. Dereure,
P. Abranches,
J. Reynes,
A. Martini,
M. Lefebvre, and J. A. Rioux.
1995.
Leishmania-human immunodeficiency virus coinfection in the Mediterranean basin: isoenzymatic characterization of 100 isolates of the Leishmania infantum complex.
J. Infect. Dis.
172:323-326[Medline].
|
| 27.
|
Rioux, J. A.,
G. Lanotte,
E. Serres,
F. Pratlong,
P. Bastien, and J. Perieres.
1990.
Taxonomy of Leishmania. Use of isoenzymes. Suggestions for a new classification.
Ann. Parasitol. Hum. Comp.
65:111-125[Medline].
|
| 28.
| Rousseau, D., S. Demartino, F. Anjuère, B. Ferrua,
K. Fragaki, Y. Le Fichoux, and J. Kubar. Sustained parasite burden
in spleen of Leishmania infantum infected BALB/c mice is
accompanied by expression of MCP-1 transcripts and lack of protection
against challenge. Eur. Cytokine Netw., in press.
|
| 29.
|
Sulahian, A.,
Y. J. F. Garin,
F. Pratlong,
J. P. Dedet, and F. Derouin.
1997.
Experimental pathogenicity of viscerotropic and dermotropic isolates of Leishmania infantum from immunocompromised and immunocompetent patients in a murine model.
FEMS Immunol. Med. Microbiol.
17:131-138[CrossRef][Medline].
|
| 30.
|
Tibayrenc, M.,
F. Kjellberg, and F. J. Ayala.
1990.
A clonal theory of parasitic protozoa: the population structures of Entamoeba, Giardia, Leishmania, Naegleria, Plasmodium, Trichomonas, and Trypanosoma and their medical and taxonomical consequences.
Proc. Natl. Acad. Sci. USA
87:2414-2418[Abstract/Free Full Text].
|
Infection and Immunity, December 2001, p. 7365-7373, Vol. 69, No. 12
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.12.7365-7373.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Nakayama, H., Loiseau, P. M., Bories, C., Torres de Ortiz, S., Schinini, A., Serna, E., Rojas de Arias, A., Fakhfakh, M. A., Franck, X., Figadere, B., Hocquemiller, R., Fournet, A.
(2005). Efficacy of Orally Administered 2-Substituted Quinolines in Experimental Murine Cutaneous and Visceral Leishmaniases. Antimicrob. Agents Chemother.
49: 4950-4956
[Abstract]
[Full Text]